Farallon Capital Management LLC Mirati Therapeutics, Inc. Transaction History

Farallon Capital Management LLC

$19.9 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 14, 2024	BUY	$41.99 - $62.38 $85 Million - $126 Million	2,024,472 New	2,024,472 $119 Million
Q3 2023 Nov 14, 2023	BUY	$27.8 - $45.35 $27.8 Million - $45.4 Million	1,001,000 New	1,001,000 $43.6 Million
Q3 2021 Nov 15, 2021	SELL	$132.13 - $177.45 $87.4 Million - $117 Million	-661,282 Reduced 73.48%	238,718 $42.2 Million
Q2 2021 Aug 13, 2021	BUY	$144.0 - $179.73 $7.2 Million - $8.99 Million	50,000 Added 5.88%	900,000 $145 Million
Q1 2021 May 17, 2021	SELL	$158.92 - $221.61 $3.97 Million - $5.54 Million	-25,000 Reduced 2.86%	850,000 $146 Million
Q3 2020 Nov 16, 2020	BUY	$113.26 - $167.27 $25.5 Million - $37.6 Million	225,000 Added 34.62%	875,000 $145 Million
Q2 2020 Aug 14, 2020	BUY	$72.01 - $120.39 $3.6 Million - $6.02 Million	50,000 Added 8.33%	650,000 $74.2 Million
Q1 2020 May 15, 2020	BUY	$69.78 - $116.21 $29.7 Million - $49.4 Million	425,000 Added 242.86%	600,000 $46.1 Million
Q4 2019 Feb 13, 2020	SELL	$70.76 - $128.86 $8.85 Million - $16.1 Million	-125,000 Reduced 41.67%	175,000 $22.6 Million
Q3 2019 Nov 14, 2019	SELL	$77.91 - $109.6 $54.1 Million - $76.2 Million	-695,000 Reduced 69.85%	300,000 $23.4 Million
Q2 2019 Aug 14, 2019	SELL	$59.49 - $104.71 $12.2 Million - $21.5 Million	-205,000 Reduced 17.08%	995,000 $102 Million
Q1 2019 May 15, 2019	SELL	$43.65 - $78.95 $4.37 Million - $7.9 Million	-100,000 Reduced 7.69%	1,200,000 $88 Million
Q4 2018 Feb 14, 2019	BUY	$32.0 - $47.43 $13.6 Million - $20.2 Million	425,000 Added 48.57%	1,300,000 $55.1 Million
Q3 2018 Nov 14, 2018	BUY	$47.1 - $62.7 $6.19 Million - $8.25 Million	131,500 Added 17.69%	875,000 $41.2 Million
Q2 2018 Aug 14, 2018	BUY	$26.05 - $52.4 $12.3 Million - $24.8 Million	473,500 Added 175.37%	743,500 $36.7 Million
Q1 2018 May 15, 2018	BUY	$17.2 - $34.95 $4.64 Million - $9.44 Million	270,000 New	270,000 $8.29 Million

Others Institutions Holding MRTX

# of Institutions

Shares Held

3.57M

Call Options Held

Put Options Held

36.6K

View Full List

About Mirati Therapeutics, Inc.

Ticker MRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,609,800
Description
Mirati Therapeutics, Inc., a clinical-stage oncology company, develops product candidates to address the genetic and immunological promoters of cancer in the United States. The company develops MRTX849, a KRAS G12C inhibitor, which is in Phase 1/2 clinical trial for treating non-small cell lung (NSCL), colorectal, pancreatic, and other cancers; ...

More about MRTX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Farallon Capital Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Farallon Capital Management LLC with notifications on news.

Account